Cochrane · systematic review · CD001797
Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy
Bus, SRM, de Haan, RJ, Vermeulen, M, et al. · Cochrane Database of Systematic Reviews · 2024 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
11
No studies
4
Included studies
NR
No studies 4 · 25%Ungraded 1 · 6.3%Very low 0 · 0%Low 0 · 0%Moderate 9 · 56.3%High 2 · 12.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyIntravenous immunoglobulin compared to placebo for chronic inflammatory demyelinating polyradiculoneuropathy
Population: people with CIDP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Significant improvement in disability within 6 weeks Intravenous immunoglobulin vs placebo | RR 2.4 [1.72, 3.36] | 5 studies · 269 participants | High |
Change in mean disability score on Rankin scale Intravenous immunoglobulin vs placebo | no estimate extracted | 3 studies · 90 participants | High |
Change in mean disability score at 24 weeks or later Intravenous immunoglobulin vs placebo | no estimate extracted | 1 study · 117 participants | Moderate Downgraded: imprecision |
Serious adverse events Intravenous immunoglobulin vs placebo | RR 0.82 [0.36, 1.87] | 3 studies · 315 participants | Moderate Downgraded: imprecision |
Intravenous immunoglobulin compared to plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy
Population: people with CIDP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Significant improvement in disability within 6 weeks Intravenous immunoglobulin vs plasma exchange | no estimate extracted | NR | No studies |
Change in mean disability score on Rankin scale Intravenous immunoglobulin vs plasma exchange | no estimate extracted | NR | No studies |
Change in mean disability score at 24 weeks or later Intravenous immunoglobulin vs plasma exchange | no estimate extracted | NR | No studies |
Serious adverse events Intravenous immunoglobulin vs plasma exchange | no estimate extracted | 1 study · 20 participants | Ungraded |
Intravenous immunoglobulin compared to prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy
Population: patients with CIDP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Significant improvement in disability within 6 weeks Intravenous immunoglobulin vs prednisolone | RR 0.91 [0.5, 1.68] | 1 study · 29 participants | Moderate Downgraded: imprecision |
Change in mean disability score on Rankin scale Intravenous immunoglobulin vs prednisolone | no estimate extracted | 1 study · 24 participants | Moderate Downgraded: imprecision |
Change in mean disability score at 24 weeks or later Intravenous immunoglobulin vs prednisolone | no estimate extracted | NR | No studies |
Serious adverse events Intravenous immunoglobulin vs prednisolone | RR 0.45 [0.04, 4.69] | 1 study · 57 participants | Moderate Downgraded: imprecision |
Intravenous immunoglobulin compared to intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy
Population: people with CIDP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Significant improvement in disability within 6 weeks Intravenous immunoglobulin vs intravenous methylprednisolone | RR 1.46 [0.4, 5.38] | 1 study · 45 participants | Moderate Downgraded: imprecision |
Change in mean disability score on Rankin scale Intravenous immunoglobulin vs intravenous methylprednisolone | no estimate extracted | 1 study · 43 participants | Moderate Downgraded: imprecision |
Change in mean disability score at 24 weeks or later Intravenous immunoglobulin vs intravenous methylprednisolone | no estimate extracted | 1 study · 45 participants | Moderate Downgraded: imprecision |
Serious adverse events Intravenous immunoglobulin vs intravenous methylprednisolone | RR 4.4 [0.22, 86.78] | 1 study · 45 participants | Moderate Downgraded: imprecision |
IVIg compared to placebo for chronic inflammatory demyelinating polyradiculoneuropathy
Population: people with chronic inflammatory demyelinating polyradiculoneuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Significant improvement in disability scale used in original study IVIg vs placebo | RR 2.4 [1.72, 3.36] | 5 studies · 2691 participants | High |
Improvement of 1 point or more on Rankin scale Better indicated by lower values IVIg vs placebo | RR 2.4 [0.98, 5.83] | 3 studies · 902 participants | Moderate Downgraded: imprecision |
Change in mean disability score on scale used in original study Better indicated by lower values IVIg vs placebo | no estimate extracted | 5 studies · 2473 participants | High |
Change in mean disability score on Rankin scale Scale from: 0 to 6. Better indicated by lower values. IVIg vs placebo | no estimate extracted | 3 studies · 904 participants | High |
Serious side effects questionnaires IVIg vs placebo | RR 0.82 [0.36, 1.87] | 3 studies · 3155 participants | High |
IVIg compared to plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy
Population: patients with chronic inflammatory demyelinating polyradiculoneuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Significant improvement in disability scale used in original study IVIg vs plasma exchange | no estimate extracted | NR | No studies |
Improvement of 1 point or more on Rankin scale IVIg vs plasma exchange | no estimate extracted | NR | No studies |
Change in mean disability score on scale used in original study The modified Neuropathy Disability Score (NDS). Better indicated by lower values IVIg vs plasma exchange | no estimate extracted | 1 study · 32 participants | Moderate Downgraded: imprecision |
Change in mean disability score on Rankin scale ‐ IVIg vs plasma exchange | no estimate extracted | NR | No studies |
Serious side effects IVIg vs plasma exchange | no estimate extracted | NR | No studies |
IVIg compared to prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy
Population: patients with chronic inflammatory demyelinating polyradiculoneuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Significant improvement in disability scale used in original study INCAT disability scale. Better indicated by lower values IVIg vs prednisolone | RR 0.91 [0.5, 1.68] | 1 study · 29 participants | Moderate |
Improvement of 1 point or more on Rankin scale IVIg vs prednisolone | no estimate extracted | NR | No studies |
Change in mean disability score on scale used in original study IVIg vs prednisolone | no estimate extracted | NR | No studies |
Change in mean disability score on Rankin scale IVIg vs prednisolone | no estimate extracted | NR | No studies |
Serious side effects questionnaires IVIg vs prednisolone | RR 0.45 [0.04, 4.69] | 1 study · 57 participants | Moderate |
IVIg compared to intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy
Population: chronic inflammatory demyelinating polyradiculoneuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Significant improvement in disability scale used in original study ONLS disability score, Better indicated by a lower score IVIg vs intravenous methylprednisolone | RR 1.46 [0.4, 5.38] | 1 study · 45 participants | Moderate |
Improvement of 1 point or more on Rankin scale Rankin scale; Better indicated by lower values IVIg vs intravenous methylprednisolone | RR 0.7 [0.22, 2.27] | 1 study · 45 participants | Moderate |
Change in mean disability score on scale used in original study Disability scale used in original study IVIg vs intravenous methylprednisolone | no estimate extracted | 1 study · 43 participants | Moderate |
Change in mean disability score on Rankin scale IVIg vs intravenous methylprednisolone | no estimate extracted | 1 study · 43 participants | Moderate |
Serious side effects questionnaires IVIg vs intravenous methylprednisolone | RR 4.4 [0.22, 86.78] | 1 study · 45 participants | Moderate |
IVIg compared to placebo for chronic inflammatory demyelinating polyradiculoneuropathy
Population: patients with chronic inflammatory demyelinating polyradiculoneuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Significant improvement in disability scale used in original study IVIg vs placebo | RR 2.4 [1.72, 3.36] | 5 studies · 2691 participants | High |
Improvement of 1 point or more on Rankin scale Rankin scale. Better indicated by lower values IVIg vs placebo | RR 2.4 [0.98, 5.83] | 3 studies · 902 participants | High |
Change in mean disability score on scale used in original study Disability scale used in original study. Better indicated by lower values IVIg vs placebo | no estimate extracted | 5 studies · 2473 participants | High |
Change in mean disability score on Rankin scale Ranskin scale. Scale from: 0 to 6. Better indicated by lower values. IVIg vs placebo | no estimate extracted | 3 studies · 904 participants | High |
Serious side effects questionnaires IVIg vs placebo | RR 0.82 [0.36, 1.87] | 3 studies · 3155 participants | High |
IVIg compared to plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy
Population: patients with chronic inflammatory demyelinating polyradiculoneuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Significant improvement in disability scale used in original study IVIg vs plasma exchange | no estimate extracted | NR | No studies |
Improvement of 1 point or more on Rankin scale IVIg vs plasma exchange | no estimate extracted | NR | No studies |
Change in mean disability score on scale used in original study The neuropathy disability score (NDS). Better indicated by lower values IVIg vs plasma exchange | no estimate extracted | 1 study · 32 participants | High |
Change in mean disability score on Rankin scale ‐ IVIg vs plasma exchange | no estimate extracted | NR | No studies |
Serious side effects IVIg vs plasma exchange | no estimate extracted | NR | No studies |
IVIg compared to prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy
Population: patients with chronic inflammatory demyelinating polyradiculoneuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Significant improvement in disability scale used in original study INCAT disability scale. Better indicated by lower values IVIg vs prednisolone | RR 0.91 [0.5, 1.68] | 1 study · 29 participants | High |
Improvement of 1 point or more on Rankin scale IVIg vs prednisolone | no estimate extracted | NR | No studies |
Change in mean disability score on scale used in original study IVIg vs prednisolone | no estimate extracted | NR | No studies |
Change in mean disability score on Rankin scale IVIg vs prednisolone | no estimate extracted | NR | No studies |
Serious side effects questionnaires IVIg vs prednisolone | RR 0.45 [0.04, 4.69] | 1 study · 57 participants | High |